An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

This story mentions weight, weight loss, and/or GLP-1 drugs. In the last few years, GLP-1s, prescription weight-loss ...

Vivani Medical, Inc. ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the successful administration of its ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

China’s obesity crisis is a sizeable profit opportunity. More than half of Chinese adults are overweight or obese — a figure expected to hit two-thirds by 2030. That is nearly 900mn people, a market ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking The ...

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development agreement. Zealand Pharma's ...

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.